The receptor tyrosine kinase family of the epidermal growth factor, which also includes HER2/neu (ErbB2), ErbB3 (HER3), and ErbB4 (HER4), includes the epidermal growth factor receptor (EGFR; ErbB1). The extracellular ligand-binding ectodomain, the single chain transmembrane domain, and the intracellular tyrosine kinase domain make up the EGFR, which is located at the cell surface. Epidermal growth factor (EGF), transforming growth factor (TGF-), amphiregulin, heparin-binding EGF, and betacellulin are just a few of the ligands that bind to and activate the EGFR.
The tyrosine kinase domain is activated by the receptors' formation of homo- or heterodimeric complexes after ligand binding. The Ras-Raf-MAP kinase, PI-3K/Akt, PKC, and Stat/Jak signaling pathways are all activated as a result of the dimerization and autophosphorylation of EGFR. The EGFR is activated to control cellular survival, differentiation, and proliferation. The EGFR has been derided as a proto-oncogene primarily because of its function in encouraging cell proliferation and preventing apoptosis.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V79022 | EGFR/BRAFV600E-IN-3 | EGFR/BRAFV600E-IN-3 is an inhibitor (blocker/antagonist) of EGFR, BRAFV600E and EGFRT790M, with IC50s of 57 nM, 68 nM and 9.70 nM respectively. | |
|
V79260 | EGFR/c-Met-IN-1 | EGFR/c-Met-IN-1 (compound TS-41) is a dual-target inhibitor of EGFR/c-Met. | |
|
V69435 | EGFR/C797S-IN-1 | 2378188-21-5 | EGFR/C797S-IN-1 is a potent inhibitor of EGFR-C797S with IC50 of 0.128 µM. |
|
V69409 | EGFR/CSC-IN-1 | 2820447-02-5 | EGFR/CSC-IN-1 is a potential dual (bifunctional) inhibitor of EGFR (IC50 10.52 nM) and cancer stem cells (CSC) for triple-negative breast cancer research. |
|
V69396 | EGFR/ErbB-2 inhibitor-1 | 1135150-79-6 | EGFR/ErbB-2 inhibitor-1 is an ErbB2/HER2 inhibitor. |
|
V69372 | EGFR/HER2-IN-6 | 2820126-50-7 | EGFR/HER2-IN-6 (compound 43) is an inhibitor (blocker/antagonist) of EGFR/HER2 and DHFR. |
|
V69383 | EGFR/HER2-IN-7 | 2820126-28-9 | EGFR/HER2-IN-7 is a potent anticancer agent with high selectivity for cancer cells and specifically acts on breast cancer cells MCF-7. |
|
V69373 | EGFR/HER2-IN-8 | 2820126-32-5 | EGFR/HER2-IN-8 (compound 34) is an inhibitor (blocker/antagonist) of EGFR/HER2 and DHFR. |
|
V69408 | EGFR/HER2-IN-9 | 1637253-79-2 | EGFR/HER2-IN-9 (Compound 1) is an EGFR and HER2 inhibitor (antagonist) with IC50s of 3.2, 8.3 and 14 nM for EGFR, EGFR T790M and HER2, respectively. |
|
V69394 | EGFR/HER2/DHFR-IN-1 | 2820126-37-0 | EGFR/HER2-IN-7 is a potent anticancer agent with high selectivity for cancer cells and specifically acts on breast cancer cells MCF-7. |
|
V79261 | EGFR/HER2/DHFR-IN-2 | EGFR/HER2/DHFR-IN-2 (Compound 4b) is an inhibitor (blocker/antagonist) of EGFR, HER2 and DHFR (IC< sub>50 are 0.248, 0.156 and 0.138 μM respectively). | |
|
V79566 | EGFR/HER2/DHFR-IN-3 | EGFR/HER2/DHFR-IN-3 (compound 4c) is a potent dual (bifunctional) inhibitor of EGFR/HER2 with IC50s of 0.138 and 0.092 μM respectively. | |
|
V69345 | Elgemtumab (LJM716) | 1512559-37-3 | Elgemtumab(LJM716) is a fully human IgG monoclonal antibody (mAb). |
|
V69420 | EMI1 | 35773-42-3 | EMI1 is a potent inhibitor of the EGFR triple mutants EGFR ex19del/T790M/C797S and EGFR L858R/T790M/C797S. |
|
V69413 | EMI48 | 34564-13-1 | EMI48 is an analogue of EMI1 and has greater potency against mutant EGFR than EMI1. |
|
V69410 | EMI56 | 2414374-41-5 | EMI56 is an analogue of EMI1 and has greater potency against mutant EGFR than EMI1. |
|
V77036 | Epidermal growth factor (EGF) (phosphate) | Epidermal growth factor (EGF) is a potent epidermal growth factor that stimulates the proliferation of epidermal cells and may be used in wound healing applications. | |
|
V69388 | Epidermal Growth Factor Receptor Peptide (985-996) | 96249-43-3 | Epidermal Growth Factor Receptor Peptide (985-996) is an amino acid (AA) polypeptide fragment derived from epidermal growth factor receptor (EGFR) 985-996 positions. |
|
V69356 | Epitinib (HMPL-813) | 1203902-67-3 | Epitinib is an orally bioactive and selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that penetrates the BBB (blood-brain barrier). |
|
V69346 | Epitinib succinate (HMPL-813 succinate) | 2252334-12-4 | Epitinib succinate is an orally bioactive and selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that penetrates the BBB (blood-brain barrier). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
